Apoptosis in leukemia: from molecular pathways to targeted therapies.
Knowledge about apoptosis pathways developed in the last few years is already being translated into novel targeted therapies. Two illustrative approaches to this process are the development of small molecule BCL2 inhibitors and X-linked inhibitors of apoptosis proteins (XIAP) inhibitors. This work demonstrates both the development of new agents based on molecular mechanisms and how these agents further our understanding of the biology of apoptosis.
Schimmer
Aaron D
AD
Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9. aaron.schimmer@utoronto.ca
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D015195:Drug Design; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human